A Novel Differential Predict Model Based on Matrix-Assisted Laser Ionization Time-of-Flight Mass Spectrometry and Serum Ferritin for Acute Graft-versus-Host Disease
Figure 3
The distribution of aGVHD and non-GVHD patients in stage 1, stage 2, and stage 3 (red, aGVHD; green, non-GVHD). (a) classification effect of the first two peaks (5910 Da; 2957.7 Da) from list of values in stage 1; (b) comparison of the expression of peak 7781.9 Da between aGVHD and non-GVHD patients in stage 1, ; (c) classification effect of the first two peaks (3245.6 Da; 2026 Da) in stage 2; (d) comparison of the expression of peak 3245.6 Da in stage 2, ; (e) classification effect of the first two peaks (2935.4 Da; 3195.6 Da) in stage 3; (f) comparison of the expression of peak 2935.4 Da in stage 3, .
